… adherence to dabigatran and even to its discontinuation [[13], [14], [15], [16]]. … of dabigatran
induced GI discomfort (DGID) and its impact on the adherence and persistence of dabigatran …

… the use of dabigatran among patients with … safety of dabigatran bid globally and stratified
by dose (110 or 150 mg bid), compared to VKA in non-Asian patients with NVAF from “real-world…

… This study was designed to evaluate the effectiveness and safety of rivaroxaban in real-world
practice compared with effectiveness and safety of dabigatran or warfarin for stroke …

… approved dabigatran etexilate … dabigatran etexilate in all approved conditions is far beyond
the scope of one article. We would particularly focus on the efficacy and safety of dabigatran …

… evaluate the safety and efficacy of dual antithrombotic therapy with dabigatran versus triple
… from 10 high-quality real-world studies to estimate the MI risk of dabigatran. In our study, the …

… -life the peak and trough dabigatran plasma concentrations over time in a very old geriatric
population, to identify the determinants of dabigatran … between dabigatran concentration and …

… real-world experiences regarding the management of the hemorrhaging patient secondary
to dabigatran … therapy trial as most of those included in this study were on dabigatran. …

… Although the dabigatran evidence was robust at the point of marketing given the large RE-…
sought to better understand the safety and effectiveness of dabigatran for stroke prevention in …

… [11] In the recently published sub-study of RE-LY that included an Asian-only population,[…
dabigatran 110 mg two times daily and 0.45%/year in patients on dabigatran 150 mg twice daily…

… In real life, D110 is indicated in older patients at higher risk of stroke or bleeding than D150.
In our populations, D110 was indeed used in older patients than D150, with more previous …